BACKGROUND: The clinical role and the potential benefit of self-measurement of blood glucose (SMBG) for patients with type 2 diabetes are still under discussion. Even less information is available on the cost-effectiveness of performing SMBG by this patient group. The goal of this study was to establish cost-effectiveness ratios of performing SMBG by patients afflicted by this disease. METHODS: We assessed the benefit and cost-effectiveness of SMBG in type 2 diabetes from a third-party payer perspective based on results of both a large epidemiologic cohort study reflecting the reality of care, and a Markov model calculation. RESULTS: Analysis of cohort study data revealed that total costs cumulated over the observation period of 8 years were lower in the SMBG group than in the non-SMBG group according to savings of euro 1'714 [oral antidiabetic drugs (OAD) only] and euro 13'815 (OAD + insulin) per patient. Several scenarios were considered in the model-based calculation. The cost-effectiveness ratio varied from euro 20'768/life year gained to domination of SMBG use compared to nonusers in OAD treated patients and from euro 59'057/life year gained to domination of SMBG use compared to nonusers in OAD + insulin treated patients. CONCLUSION: Results indicate that SMBG in type 2 diabetes offers an excellent opportunity to get a high investment-outcome ratio in the treatment of this pandemic disease.
BACKGROUND: The clinical role and the potential benefit of self-measurement of blood glucose (SMBG) for patients with type 2 diabetes are still under discussion. Even less information is available on the cost-effectiveness of performing SMBG by this patient group. The goal of this study was to establish cost-effectiveness ratios of performing SMBG by patients afflicted by this disease. METHODS: We assessed the benefit and cost-effectiveness of SMBG in type 2 diabetes from a third-party payer perspective based on results of both a large epidemiologic cohort study reflecting the reality of care, and a Markov model calculation. RESULTS: Analysis of cohort study data revealed that total costs cumulated over the observation period of 8 years were lower in the SMBG group than in the non-SMBG group according to savings of euro 1'714 [oral antidiabetic drugs (OAD) only] and euro 13'815 (OAD + insulin) per patient. Several scenarios were considered in the model-based calculation. The cost-effectiveness ratio varied from euro 20'768/life year gained to domination of SMBG use compared to nonusers in OAD treated patients and from euro 59'057/life year gained to domination of SMBG use compared to nonusers in OAD + insulin treated patients. CONCLUSION: Results indicate that SMBG in type 2 diabetes offers an excellent opportunity to get a high investment-outcome ratio in the treatment of this pandemic disease.
Entities:
Keywords:
CEA; SMBG; cost-effectiveness; costs; diabetes mellitus type 2; self-measurement of blood glucose
Authors: M C Weinstein; E L Toy; E A Sandberg; P J Neumann; J S Evans; K M Kuntz; J D Graham; J K Hammitt Journal: Value Health Date: 2001 Sep-Oct Impact factor: 5.725
Authors: V Gozzoli; A J Palmer; A Brandt; C Weiss; W Piehlmeier; R Landgraf; R Renner Journal: Dtsch Med Wochenschr Date: 2000-09-29 Impact factor: 0.628